Downloads
Abstract
Objectives: To evaluate the efficacy of endocrine combined with CDK4/6 inhibitors in patients with hormone receptor - positive, HER2 - negative recurrent or metastatic breast cancer.
Methods: A retrospective and prospective descriptive study on 61 patients diagnosed with hormone receptor - positive, HER2 - negative metastatic or recurrent breast cancer at K Hospital from January 2020 to October 2022.
Result: The mean age was 54.0 years. The majority of patients relapsed after 2 years of radical treatment, accounting for 75%. The most common metastatic sites were bone, lung and liver, respectively, accounting for 70.5%, 36.0% and 24.6%. The overall response rate of the regimen was 45.9%. The complete response rate was 1.6%, the partial response rate was 44.3%, 31.1% of the patients were stable. The overall response rate in first - line therapy was better than that in the second - line of treatment (ORR: 67,5% vs 37,5%; p = 0,039). The response rate in the first line and subsequent lines were 58.8% and 29.6%, respectively, the difference was statistically significant with p = 0.023. Median progression - free survival was 17 months.
Conclusion: Endocrine combined with CDK4/6 inhibitors is effective in high response rates and progression - free survival for patients with recurrent or metastatic of hormone receptor - positive, HER2 - negative breast cancer. This regimens may be more widely used in clinical practice
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
Maaren MC van, Munck L de, Strobbe LJA, et al. Tenyear recurrence rates for breast cancer subtypes in the Netherlands: A large population based study. Int J Cancer. 2019;144(2):263-272.
Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016; 375: 1925
Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptorpositive,HER2-negative advanced breast cancer. Ann Oncol 2018; 29: 1541
Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor- positive, HER2 - negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, doubleblind, phase 3 randomised controlled trial. Lancet Oncol 2016; 17:425
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514–24.
Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307–16.
Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(20):3271-3277.
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(15Pt 1):4429-4434.
Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638-2645.
Begum N, Mehmood T. Literature review of visceral and non-visceral metastatic breast cancer. Ann Oncol. 2017;28:x32.
| Published | 28-12-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 88 (2023) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.88.1 | |
| Keywords | Ung thư vú tái phát di căn, thụ thể nội tiết dương tính, HER2 âm tính, CDK4/6 Recurrent or metastatic breast cancer, hormone receptor - positive, HER2 - negative, CDK4/6 |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Journal of Clinical Medicine Hue Central Hospital